BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Decision ensures continued patient access to VENDAJE^® and VENDAJE AC^®

POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today commented on the withdrawal of all seven of the Centers for Medicare & Medicaid Services’ (“CMS”) Local Coverage Determinations (“LCD”) for skin substitute grafts/cellular and tissue-based products for the treatment of diabetic foot ulcers (“DFU”) and venous leg ulcers (“VLU”) that would have been effective on January 1, 2026.